Articles tagged with 'Press Release' | BIOTRONIK

BIOTRONIK - Archive (Press Release)

2022
25
November
2022
| 09:00 Europe/Amsterdam
BIOTRONIK announced the presentation of one-year results from the investigator-initiated BIOPACT RCT this week by Principal Investigator Dr. Koen Deloose at the Paris Vascular Insights 2022 congress. The randomized controlled non-inferiority trial ev...
Read more
20
September
2022
| 15:41 Europe/Amsterdam
BIOTRONIK announced the presentation of new full-cohort 2-year BIOSOLVE-IV data. In a poster session at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2022, principal investigator Prof. Dr. Johan Bennett presented the recent findings ...
Read more
20
September
2022
| 15:29 Europe/Amsterdam
In the “TCT Innovation” session Prof. Michael Haude, BIOMAG-I Coordinating Clinical Investigator, presented the new BIOMAG-I study results at the Transcatheter Cardiovascular Therapeutics (TCT) 2022. The multi-center study assesses the angiographic, ...
Read more
26
July
2022
| 17:06 Europe/Amsterdam
BIOTRONIK announced that it received U.S. Food and Drug Administration (FDA) approval of its innovative Pulsar®-18 T3 peripheral self-expanding stent system for an improved implantation procedure for endovascular treatments. The company also announce...
Read more
06
July
2022
| 09:37 Europe/Amsterdam
BIOTRONIK announced the presentation of two studies on the performance of its drug-coated balloon catheter Passeo®-18 Lux® at this year’s LINC congress in Leipzig, Germany. The BIO REACT study was designed to better understand when and where a stent ...
Read more
05
July
2022
| 10:14 Europe/Amsterdam
A BIO-RESORT subgroup analysis of outcomes in small coronary vessels (<2,5mm) evaluated the efficacy and safety of three contemporary DES including BIOTRONIK’s ultrathin struts drug-eluting stent (DES) Orsiro® at 5 years. The results of the analysis ...
Read more
17
May
2022
| 09:32 Europe/Amsterdam
Two posters presented at the EuroPCR provided new insights into the safety profile of BIOTRONIK's Magmaris® Resorbable Magnesium Scaffold (RMS). BIOSOLVE-IV study investigator Prof. Dr. Jan Torzewski, Cardiovascular Center Oberallgäu-Kempten, Germany...
Read more
28
April
2022
| 08:13 Europe/Amsterdam
New long-term data presented at Charing Cross demonstrated the safety of BIOTRONIK’s Passeo®-18 Lux® paclitaxel drug-coated balloon (DCB) for the treatment of peripheral artery disease (PAD) in infrainguinal arteries. The independent analysis was led...
Read more
05
April
2022
| 07:18 Europe/Amsterdam
Final results from the BIO|GUARD-MI study show a 31 percent reduction of MACE in a sub-group analysis of patients with non-ST segment elevation myocardial infarction (NSTEMI). In the primary endpoint analysis of the total patient population, a trend ...
Read more
04
April
2022
| 11:25 Europe/Amsterdam
COMUNICADO DE PRENSA - PARA PERSONAL SANITARIOBIOTRONIK anunció hoy la introducción de una nueva actualización de la aplicación móvil para pacientes con dispositivos cardíacos, diseñada para facilitar el intercambio con el personal clínico e involucr...
Read more
30
March
2022
| 09:20 Europe/Amsterdam
BERLIN, Germany – BIOTRONIK announced today the introduction of a new mobile app update for cardiac device patients which is designed to facilitate exchange with clinical staff and to better engage patients in their care. The Patient App can be used ...
Read more
21
March
2022
| 09:27 Europe/Amsterdam
BIOTRONIK today announced the CE approval for HeartInsight®, its remote heart failure (HF) management solution that accurately identifies patients at higher risk of HF decompensation early on. HeartInsight predicts two out of three HF hospitalization...
Read more
01
March
2022
| 09:27 Europe/Amsterdam
BIOTRONIK today announced final enrollment in the BIOMAG-I clinical trial1 by Prof. Michael Haude, Germany, the study’s coordinating clinical investigator and the principal investigator Prof. Javier Escaned, Spain. The prospective single-arm study as...
Read more
28
February
2022
| 14:27 Europe/Amsterdam
BIOTRONIK today announced five-year data from the BIOFLOW-V trial, which was presented yesterday at the 2022 CRT Conference during a late-breaking-clinical-trial session by Dr. David Kandzari, US Principal Investigator, Piedmont Heart Institute, Atla...
Read more
2021
08
November
2021
| 09:09 Europe/Amsterdam
Superiority of the Magmaris® sirolimus-eluting bioresorbable magnesium scaffold with regard to probable or definite scaffold thrombosis compared to a historical control group of Absorb scaffold data was demonstrated for the first time in a prospectiv...
Read more
30
September
2021
| 10:35 Europe/Amsterdam
BIOTRONIK announced today it received U.S. Food and Drug Administration (FDA) approval of its Orsiro® Mission bioabsorbable polymer coronary drug-eluting stent system (BP-DES). The company also announced the first US implant and full commercial avail...
Read more
27
September
2021
| 11:03 Europe/Amsterdam
 BIOTRONIK is proud to announce the enrollment of the first patient in the BIONETIC-I study of the safety and efficacy of the Dynetic®-35 cobalt chromium balloon-expandable stent system for the treatment of atherosclerotic peripheral artery disease l...
Read more
23
September
2021
| 08:53 Europe/Amsterdam
BIOTRONIK is proud to announce the completion of enrollment of the investigator-initiated BIOPACT randomized controlled trial (RCT). This non-inferiority study evaluates the safety and efficacy of paclitaxel drug-coated balloons (DCBs), comparing the...
Read more
15
September
2021
| 09:28 Europe/Amsterdam
BIOTRONIK is pleased to announce the expansion of the Fortress® reinforced introducer sheath line, which is now available in 7- and 8F-compatible sizes in the United States and countries that recognize European CE Mark approval.  The Fortress introdu...
Read more
20
August
2021
| 11:58 Europe/Amsterdam
BIOTRONIK has today announced an important online symposium hosting the principal investigator of the TRUST Trial1, the latest study calling for a reform to the current clinical standards for in-person patient evaluations (IPE), as part of this year’...
Read more
18
August
2021
| 09:01 Europe/Amsterdam
A study published in EUROPACE this week confirms that heart failure (HF) decompensation can be predicted early when monitored using an algorithm that combines existing remote monitoring trends and baseline risk stratification.The multi-center SELENE ...
Read more
28
July
2021
| 11:30 Europe/Amsterdam
In association with Heart Rhythm 2021, BIOTRONIK today announced that the latest implantable cardiac monitor (ICM), BIOMONITOR IIIm, has been recognized by internationally-renowned research analysts Frost & Sullivan as high-performing across a range ...
Read more
17
June
2021
| 09:30 Europe/Amsterdam
BIOTRONIK has today announced an online event which will discuss insights from a recent study1 that focused on comparing stylet-driven pacing leads with lumen-less leads, that are currently industry standard for left-bundle branch area pacing (LBBAP)...
Read more
18
May
2021
| 09:00 Europe/Amsterdam
New, long-term follow-up data from the BIOSOLVE-IV real-world registry strengthens the clinical evidence for BIOTRONIK’s Magmaris® Resorbable Magnesium Scaffold (RMS) as a therapy option for patients with coronary artery disease. Prof. Jan Torzewski,...
Read more
12
May
2021
| 10:22 Europe/Amsterdam
BIOTRONIK has today announced a virtual live event series, for implanting cardiologists, kicking off next week. The series will explore the clinical applications of the newest suite of Conduction System Pacing (CSP) tools, released by the company.The...
Read more
21
April
2021
| 09:08 Europe/Amsterdam
BIOTRONIK has today unveiled the newest suite of tools for the more specialized implanting procedures in the His-bundle cardiac conduction system. The company will present the tools to cardiologists this week as part of European Heart Rhythm Associat...
Read more
20
April
2021
| 08:18 Europe/Amsterdam
BIOTRONIK has announced a satellite symposium taking place at this week’s European Heart Rhythm Association’s (EHRA) online congress: ‘Less is more: Do we still need an atrial lead for atrial sensing?’. Expert physicians will discuss key outcomes fro...
Read more
15
March
2021
| 14:42 Europe/Amsterdam
BIOTRONIK’s ultrathin-strut stent, Orsiro®*, demonstrated superiority over Xience DES for target lesion failure (TLF) at 24 months, according to new follow-up data from the BIOSTEMI trial.1The latest results were presented by Prof. Thomas Pilgrim, In...
Read more
01
February
2021
| 10:45 Europe/Amsterdam
Recent data from the investigator-initiated, randomized controlled trial (RCT), BIOLUX AV, showed that the treatment of patients with dysfunctional hemodialysis access (HA), with BIOTRONIK’s Passeo®-18 LuxTM drug-coated balloon (DCB)*, is safe and ef...
Read more